Administratiekantoor Westend Stichting
CIK 1460840 · last filed 2026-06-17
Administratiekantoor Westend Stichting is a corporate insider who has filed 10 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing shows the insider sold $1.90B of CAVA on Jun 17, 2026. Across all open-market trades the lifetime net is −$7.35B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.08B across reported positions. 74 SEC filings were submitted jointly with Westend S.A.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.08B
7
10
-$7.35B
Filer Profile
AMSTERDAM 1096 AS
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAVA | Director | 6,507,990 | $52.47 | $341.44M | -$3.02B | 2 | 2026-06-17 |
| LXRX | Director | 136,180,481 | $1.82 | $248.53M | $78.92M | 3 | 2024-05-14 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 84,891 | $15.70 | $1.33M | $5.70M | 1 | 2023-02-23 |
| SQZ Biotechnologies Co (SQZ) Delisted | 10%+ Owner | 1,141,308 | $0.43 | $496.5K | $66.96M | 1 | 2020-11-03 |
| BUFF | Director | 114,987,547 | $54.07 | $6.22B | -$4.55B | 1 | 2015-07-27 |
| WTW | 10%+ Owner | 11,064,908 | $295.39 | $3.27B | $20.41M | 1 | 2014-08-14 |
| Ceres, Inc. (CERE) Delisted | 10%+ Owner | 341,252 | $44.96 | $15.34M | $55.00M | 1 | 2012-02-28 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | CAVA | Sell (S) | −21,000,000 | -$1.90B | EDGAR |
| 2024-05-14 | LXRX | Mixed | +575,461,000 | $0 | EDGAR |
| 2024-02-29 | CAVA | Sell (S) | −21,000,000 | -$1.13B | EDGAR |
| 2023-02-23 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +3,200,000 | $5.70M | EDGAR |
| 2022-08-09 | LXRX | Buy (P) | +24,260,700 | $60.65M | EDGAR |
| 2020-11-03 | SQZ Biotechnologies Co (SQZ) Delisted | Mixed | +14,456,772 | $66.96M | EDGAR |
| 2017-11-17 | LXRX | Buy (P) | +1,807,270 | $18.27M | EDGAR |
| 2015-07-27 | BUFF | Sell (S) | −227,716,824 | -$4.55B | EDGAR |
| 2014-08-14 | WTW | Buy (P) | +886,340 | $20.41M | EDGAR |
| 2012-02-28 | Ceres, Inc. (CERE) Delisted | Mixed | +20,284,675 | $55.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.